

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 5 | — | — | 5 |
| Muscle spasticity | D009128 | — | — | — | — | 5 | — | — | 5 |
| Sclerosis | D012598 | — | — | — | — | 1 | — | — | 1 |
| Drug common name | Arbaclofen |
| INN | arbaclofen |
| Description | Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H](CC(=O)O)c1ccc(Cl)cc1 |
| PDB | — |
| CAS-ID | 69308-37-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL301742 |
| ChEBI ID | — |
| PubChem CID | 11281011 |
| DrugBank | DB08891 |
| UNII ID | NYU6UTW25B (ChemIDplus, GSRS) |
